UNSPSC 51392203: Clonidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H9Cl2N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MN3L5RMN02, chemically known as 2,6-dichloro-n-imidazolidin-2-ylideneaniline but generally known as clonidine, which bears US NIH Compound Identifier 2803. European Medicines Agency schedules Clonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06730MIG.

UNSPSC 51392203 Clonidine, a Commodity code, nominally addresses a specific pharmaceutical ingredient but shows limited direct alignment with recent state and local procurement activity. The two recent opportunities tagged under this code diverge substantially from the code's narrow scope: Seminole County, Florida posted an IFB for naloxone and drug deactivation systems (naloxone is a distinct pharmaceutical product, not clonidine), and the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer prescription fulfillment models for a broader Therapeutic Pharmacy Initiative. The actual work being solicited under this code tag encompasses pharmaceutical procurement and pharmacy benefit program design, with issuing bodies spanning county health departments and state HHS agencies. Neither opportunity targets clonidine specifically, suggesting the code may be misapplied in the recent postings or the code's practical scope extends to broader pharmaceutical product families in state and local health procurement.

Activity under this code shows geographic concentration in Texas and Florida, with no additional jurisdictions represented in the available recent-opportunities block. Seminole County's IFB (Solicitation IFB60459723LAS, due Jul 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, requiring electronic bid submission and E-Verify compliance. The Texas HHS Commission's RFI (HHS0017013, posted Apr 3, 2026, response deadline Apr 3, 2026) was exploratory market intelligence gathering on direct-to-manufacturer prescription programs for self-insured state employees and health plans, with no formal evaluation criteria or award values specified at the RFI stage. The mismatch between the code's nominal scope and the actual pharmaceutical work being procured suggests either inconsistent coding practices in state-local procurement systems or a broader interpretation of the code to encompass general pharmaceutical products and pharmacy services beyond the chemical compound specified by the code name.